Marseille, France

Aime Crevat

This inventor holds 1 USPTO granted patent. Top assignee: Adir Et Compagnie. Active years: 1998.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Aime Crevat: Innovator in Chemical Compounds

Introduction

Aime Crevat is a notable inventor based in Marseille, France. He has made significant contributions to the field of chemistry, particularly in the development of novel compounds. His work has led to the creation of a patent that showcases his innovative approach to chemical formulations.

Latest Patents

Aime Crevat holds a patent for N-benzylpiperazine compounds. This patent includes a compound of formula (I), where R₁ represents linear or branched (C₁ -C₆) alkyl. This invention highlights his expertise in synthesizing complex chemical structures that may have various applications in pharmaceuticals and other industries. He has 1 patent to his name.

Career Highlights

Crevat is associated with Adir et Compagnie, a company that focuses on chemical innovations. His role there has allowed him to explore and develop new chemical compounds that contribute to advancements in the field. His work is characterized by a commitment to research and development, which has positioned him as a valuable asset in his industry.

Collaborations

Throughout his career, Aime Crevat has collaborated with esteemed colleagues such as Jean-Paul Tillement and Bernard Testa. These partnerships have fostered an environment of innovation and have led to the successful development of various chemical compounds.

Conclusion

Aime Crevat is a distinguished inventor whose work in chemical compounds has made a significant impact in his field. His patent for N-benzylpiperazine compounds exemplifies his innovative spirit and dedication to advancing chemical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…